We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer’s Metastatic Colorectal Cancer Drug Submitted for Approval in U.S., EU
Bayer’s Metastatic Colorectal Cancer Drug Submitted for Approval in U.S., EU
June 1, 2012
Bayer HealthCare has submitted applications to the FDA and European Medicines Agency for its metastatic colorectal cancer treatment regorafenib.